? Cancer Control Program The Cancer Control Program (CCP) is a highly collaborative and transdisciplinary Program that focuses on identifying and analyzing the genetic, behavioral, and health care determinants of cancer susceptibility and outcomes in diverse and vulnerable populations and on developing, evaluating and implementing interventions to lower risk and improve cancer outcomes. CCP is one of two Population Science Research Programs of the Abramson Cancer Center (ACC). CCP has 39 members who work intra- and inter-Programmatically to apply advances in science to population health and cutting-edge data analytics, address the cancer burdens and risk factors in our catchment area, and train the next generation of cancer control researchers. Members conduct research within four broad and interconnected Program aims: 1) Cancer Genomics and Risk; 2) Communication and Health Behavior; 3) Cancer Survivorship; and 4) Health Care Outcomes. CCP has produced a substantial body of high impact work in the current funding period. In Cancer Genomics and Risk, members have established the basis for clinical management of individuals with moderate penetrance risk genes for breast and colorectal cancer, identified risk loci associated with susceptibility to testicular germ cell tumors, and established the comparable efficacy of genetic counseling delivered through telehealth. In Communication and Health Behavior, members have conducted innovative studies on the use of incentives for improving early detection and novel transdisciplinary research in diet, obesity and cancer. In Cancer Survivorship, members have established clinical paradigms for cancer survivors through patient-centered care plans and have revealed important complexities in end of life care. In Health Outcomes, members have innovated methods to use the electronic health record to improve health behaviors and have conducted pragmatic trials to innovate new models of high-quality cancer care. CCP recruited 17 new members during the current funding period in the areas of epidemiology, genomics, biostatistics, informatics, nutrition and the microbiome. CCP works closely with the Tobacco and Environmental Carcinogenesis Program to create a robust population science presence at the ACC. CCP members come from ten departments in the Perelman School of Medicine, School of Nursing, Wharton School of Business, and Annenberg School for Communication. There have been 640 cancer-related publications over the current funding period (13% intra- Programmatic, 35% inter-Programmatic, 76% multi-institutional). Members have 30 R01-equivalents, $14.5M (direct) in annual cancer-related research funding, of which $11.6M is peer-reviewed and $3.8M is from NCI. During the funding period, CCP members enrolled 10,768 subjects onto interventional trials (with 819 onto treatment trials) and 2,923 subjects onto non-interventional trials. In sum, CCP is a vibrant community of interactive population science investigators working across four inter-connected aims to further research impacting our catchment area and beyond.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016520-45
Application #
10088749
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-15
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Jang, Jeong Hoon; Manatunga, Amita K; Taylor, Andrew T et al. (2018) Overall indices for assessing agreement among multiple raters. Stat Med 37:4200-4215
Romero, Sally A D; Brown, Justin C; Bauml, Joshua M et al. (2018) Barriers to physical activity: a study of academic and community cancer survivors with pain. J Cancer Surviv 12:744-752
Scheel, John R; Kim, Eunhee; Partridge, Savannah C et al. (2018) MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol 210:1376-1385
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Hordeaux, Juliette; Wang, Qiang; Katz, Nathan et al. (2018) The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. Mol Ther 26:664-668
Raghunathan, Nirupa Jaya; Korenstein, Deborah; Li, Qing S et al. (2018) Determinants of mobile technology use and smartphone application interest in cancer patients. Cancer Med 7:5812-5819
Torre, Eduardo; Dueck, Hannah; Shaffer, Sydney et al. (2018) Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH. Cell Syst 6:171-179.e5
Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N et al. (2018) Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10:

Showing the most recent 10 out of 1047 publications